Results 201 to 210 of about 216,217 (284)

Uncovering the Role of Neuropsychiatric Symptoms in Cognitive Impairment Progression. [PDF]

Proceedings (IEEE Int Conf Bioinformatics Biomed)
Jeon E, Garg M, Liu X, Vassilaki M, St Sauver J, Petersen RC, Sohn S.   +6 more
europepmc   +1 more source

Medication Knowledge of Patients with Parkinson's Disease: Strengths and Gaps

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Effective drug treatment of motor and non‐motor symptoms in Parkinson's disease (PD) often requires the administration of several anti‐Parkinson drugs in complex treatment regimens. The successful autonomous application of drugs places high demands on therapy adherence, which in turn relies on sufficient medication knowledge ...
Stephan Greten, Sarana Ulaganathan, Johannes Heck, Lan Ye, Matthias Höllerhage, Christoph Schrader, Corinna Ziemann, Olaf Krause, Florian Wegner, Martin Klietz   +9 more
wiley   +1 more source

Documented End‐of‐Life Preferences of People With Parkinson's Disease or Parkinsonism Across Europe

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease and atypical parkinsonism are characterized by motor and non‐motor symptoms. As the disease advances, planning for end‐of‐life (EoL) care becomes increasingly important. However, consensus‐based European guidelines for advance care planning and documentation of EoL care preferences for parkinsonism are lacking ...
Bauke W. Dijkstra, Catharina Muente, Michela Garon, Kristina Rosqvist, Monica Scharfenort, Katharina M. Lex, Philip Poku, Eirini Nixina, Pille Taba, Ülle Krikmann, Katrin Sikk, Katie Flanagan, Anette E. Schrag, Spyros Konitsiotis, Miltiadis Makrydimas, Stefan Lorenzl, Per Odin, David J. Pedrosa, Kris C.P. Vissers, Marieke M. Groot, Bastiaan R. Bloem, Marjan J. Meinders, Angelo Antonini, the PD_Pal consortium, Argyri Tsakanika, Dhaval Trivedi, Dimitri Gatsios, Dimitrios Fotiadis, K. Ray Chaudhuri, Nikolaos Moschos, Piret Paal   +30 more
wiley   +1 more source

Patterns and Trajectories of Behavioral and Neuropsychiatric Symptoms in Frontotemporal Dementia and Primary Progressive Aphasia. [PDF]

Neurology
Marth L, Martinez-Murcia FJ, Górriz-Sáez JM, Denecke J, Ewers M, Prix C, Stockbauer AC, Bernhardt AM, Wagemann O, Wlasich E, Kustermann J, Peters O, Hellmann-Regen J, Droste Zu Senden L, Priller J, Spruth EJ, Spottke A, Asperger H, Schroeck F, Gamez A, Schneider A, Fliessbach K, Dinter E, Linn J, Günther R, Wiltfang J, Schott BH, Bähr M, Zerr I, Flöel A, Malinowski R, Buerger K, Janowitz D, Duzel E, Glanz W, Lüsebrink F, Teipel SJ, Kilimann I, Prudlo J, Hermann A, Synofzik M, Mengel D, Beichert L, Müller D, Petzold GC, Yakupov R, Hetzer S, Dechent P, Scheffler K, Schönecker S, Levin J.   +50 more
europepmc   +1 more source

The Spectrum of Abnormal Tongue Movements: Review of Phenomenology, Etiology, and Differential Diagnosis

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Classifying abnormal tongue movements is challenging due to their varied presentations and limited visibility compared to other body parts. Accurate identification of the phenomenology guides physical examination and can point to specific diagnoses.
Nathaniel Bendahan, Seyed‐Mohammad Fereshtehnejad, Christos Ganos, Emily Swinkin, Anthony E. Lang   +4 more
wiley   +1 more source

Continuous Subcutaneous Versus Intestinal Levodopa Infusion for Parkinson's Disease: A Real‐World, Monocentric, Observational Study and Critical Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Subcutaneous foslevodopa‐foscarbidopa (SCFF) is a novel, non‐surgical dopaminergic infusion therapy for better controlling motor fluctuations in advanced Parkinson's disease (PD). However, there are scarce real‐world data on efficacy, adverse events and comparisons with other infusion strategies. Objectives Here, we aimed to provide
Johannes Hartig, Lennert Sitzmann, Doreen Hartenstein, Marion Labisch, Chi Wang Ip, Jens Volkmann, Christine Daniels   +6 more
wiley   +1 more source

Risk‐Benefit Considerations in Deep Brain Stimulation Discontinuation for Late‐Stage Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Management of deep brain stimulation (DBS) in late‐stage Parkinson's disease (LSPD) remains challenging, particularly when deciding whether to continue or discontinue stimulation, and evidence on risk–benefit considerations is limited. Objectives To identify key factors to improve decision‐making in DBS management for LSPD patients.
Pietro Antenucci, Andrea Gozzi, Fabiana Colucci, Federica Pes, Jay Guido Capone, Alba Scerrati, Michele Alessandro Cavallo, Maura Pugliatti, Daniela Gragnaniello, Mariachiara Sensi   +9 more
wiley   +1 more source